United Therapeutics Corporation is a biotechnology company dedicated to developing and commercializing innovative therapies for patients with chronic and life-threatening conditions. The company has four approved products, primarily targeting pulmonary arterial hypertension (PAH), a rare and progressive disease characterized by elevated blood pressure in the lung arteries. United Therapeutics focuses on the prostacyclin pathway in its PAH treatments, many of which are based on the molecule treprostinil. Although most of its sales are generated in the United States, the company is committed to expanding its reach globally. In addition to its PAH therapies, United Therapeutics also markets a pediatric oncology drug, while maintaining a strong emphasis on addressing the unmet medical needs associated with pulmonary arterial hypertension and other complex health challenges.
SteadyMed Ltd. is a medical-device company pursuing innovative devices for delivering injectable therapeutic drugs for pain relief, diabetes and other chronic conditions.
The company's products are pre-filled drug-infusion patches that will be sold in conjunction with a series of pharma and device companies. Specific applications of the device will be tailored in accordance with the requirements of the company's partners.
Celularity is a clinical-stage biotechnology company focused on developing innovative therapies using allogeneic cells and tissues derived from postpartum placenta. The company specializes in off-the-shelf placental-derived cell therapies, including both genetically modified and unmodified natural killer (NK) cells, engineered T cells such as CAR-T cells, and mesenchymal-like adherent stromal cells. These therapies are designed to treat a range of conditions, including cancer, autoimmune diseases, and degenerative disorders, while also enhancing immunity and promoting healing. Celularity operates through three main business segments: Cell Therapy, Degenerative Disease, and bio-banking, with the bio-banking segment contributing the majority of its revenue. The company aims to enable patients to initiate treatment more rapidly, thereby improving medical outcomes.
The University of Alabama at Birmingham (UAB) is a prominent institution located in Birmingham, Alabama, established in 1969. It offers a wide range of academic programs, with over 130 areas of study, including bachelor's, master's, doctoral, and professional degrees across various disciplines such as arts, sciences, business, education, engineering, and public health. UAB is particularly recognized for its medical school and one of the largest university medical centers in the United States. The university boasts a diverse student body, including many distinguished scholars who have received prestigious awards. UAB fosters a vibrant student life with over 150 organizations, active Greek life, and comprehensive recreational facilities. Financial aid and departmental fellowships are available to help eligible students cover tuition costs. UAB's mission extends beyond education, serving the community and addressing global challenges through research and innovation.
Revivicor is a regenerative medicine company focused on applying leading-edge animal biotechnology platforms to provide a superior quality, high-volume, human-compatible, alternative tissue source for treatment of human degenerative disease.
Transoma Medicalis a provider of implantable wireless diagnostic systems for patients with chronic cardiovascular disease and for biomedical research. The company’s products include small wireless sensors that transmit information from inside the body to a receiver via radio-frequency waves, as well as unique software to condense the data these devices provide into meaningful information.
Cooke Pharma
Acquisition in 2000
Cooke Pharma is a privately held company and is the exclusive maker of the HeartBar line of arginine-enriched products.
Medicomp develops, manufactures, and provides service with the most reliable and sophisticated ambulatory heart-monitoring systems.
SynQuest, Inc.
Acquisition in 1999
SynQuest, Inc. is a company that manufactured treprostinil, the bulk active ingredient in Remodulin.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.